Clinical Combinations Including PD-1 or PD-L1 Inhibitors Demonstrate More Clinical Activity

In this study, most clinical combinations including PD-1 or PD-L1 inhibitors demonstrated more clinical activity than the monotherapy activity of the checkpoint inhibitor alone.

Source: CancerNetwork - February 17, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news